A study analysing the immune cell composition of cerebrospinal fluid using scRNA-seq in MS and non-MS neuroinflammatory conditions (ONID)
Latest Information Update: 05 Nov 2020
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis; Neurogenic inflammation
- Focus Pharmacodynamics
- 05 Nov 2020 New trial record
- 13 Sep 2020 Results presented at the 8th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis